Full-Time

Senior Director

Clinical Research, Oncology

Posted on 4/3/2025

Eikon Therapeutics

Eikon Therapeutics

201-500 employees

Develops therapies with single-molecule tracking

Compensation Overview

$270k - $294.5k/yr

+ Bonus + Equity

San Bruno, CA, USA + 1 more

More locations: New York, NY, USA

Hybrid

On-site presence required: minimum 3 days per week in CA or NJ offices.

Category
Biology & Biotech (2)
,
Required Skills
Google Cloud Platform
Requirements
  • MD or DO degree with significant experience in Oncology
  • Minimum of 5-7 years of clinical experience, including 3+ years in drug development
  • Significant experience in clinical practice with direct patient care (preferably in Oncology)
  • Proven track record in leading clinical trials, including medical monitoring of early and late clinical trials and managing complex projects
  • In-depth knowledge of clinical research methodologies, GCP, and regulatory requirements
  • Ability to work effectively in a matrixed environment
  • Strong analytical, organizational, and problem-solving skills
  • Excellent communication and interpersonal skills, with the ability to collaborate effectively with cross-functional teams and external partners
  • Passion for innovation and improving patient outcomes
Responsibilities
  • Design and conduct early-stage or late-stage clinical development trials, including, but not limited to: assessing clinical safety and efficacy data, performing medical monitoring, and be responsible for other study-related clinical activities.
  • Work closely with biomarker, discovery, and translational research scientists.
  • Interpret reports, prepare oral and written results of product research, and participate in the discussion of strategies formulated within the disease areas that Eikon is focusing on.
  • Collaborate closely with Clinical Science and other relevant functions within Eikon and potential partners including discovery, translational, and biomarker research scientists, toxicologists, clinical pharmacologists, drug safety specialists, regulatory representatives, as well as personnel from Global Clinical Operations, and other support functions.
  • Establish strong working relationships and collaborations with external study investigators, key opinion leaders in drug development, and external alliance partners.
  • Work closely with functional partners (Data Management, Clinical Operations, Biostatistics, Regulatory) to ensure an integrated and strategic approach to flawless execution and systematic oversight of study protocol(s) in clinical development in close collaboration with key functional stakeholders.
  • Work in partnership with colleague study responsible physicians and clinical scientists to ensure development of high-quality study protocols including use of consistent processes/standards across studies.
  • Work closely with functional partners to address protocol questions from Health Authorities and Ethics Committees in a consistent fashion.
Desired Qualifications
  • Experience with IND and/or NDA filings is preferred

Eikon Therapeutics discovers and develops new medicines by studying the behavior of biological systems. The company uses a proprietary single-molecule tracking (SMT) platform combined with artificial intelligence to visualize and measure protein motion in living cells in real-time. Unlike competitors that often rely on static snapshots of chemical processes, Eikon focuses on the dynamic aspects of biology to identify drug targets with high precision. Its goal is to leverage this large-scale molecular data to invent and commercialize therapies for patients with serious diseases.

Company Size

201-500

Company Stage

IPO

Headquarters

Hayward, California

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Raised $381M IPO February 2026 funds operations to H2 2027.
  • $350.7M Series D and Millbrae expansion boost capacity by May 2027.
  • EIK1001 Phase II NSCLC data debuts ESMO 2025, pivotal trials ahead.

What critics are saying

  • EIK1001 NSCLC Phase II fails efficacy, halts Phase II/III in 3-6 months.
  • PARP1 inhibitors EIK1003/EIK1004 discontinued for hematological toxicities in 6-12 months.
  • Cash exhausts mid-2027 as platform yields no new targets without partnerships.

What makes Eikon Therapeutics unique

  • Nobel-winning single-molecule tracking visualizes protein motion in live cells.
  • Founders Eric Betzig and Robert Tjian industrialize super-resolution microscopy.
  • AI and automation inventory molecular interactions at unprecedented scale.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

Medical (premiums covered by Eikon at 95%)

Dental Insurance

Vision Insurance

Mental Health Support

Unlimited Paid Time Off

Paid Holidays

Life Insurance

Enhanced Parental Leave

Daily subsidized lunch program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
The Gridley Herald
Mar 30th, 2026
Eikon Therapeutics raises $381M in upsized IPO to advance cancer drug pipeline

Eikon Therapeutics, a late-stage clinical biopharmaceutical company, reported fourth quarter and full year 2025 financial results. The company completed an upsized IPO in February 2026, raising $381 million in gross proceeds. Eikon is advancing multiple clinical programmes, including EIK1001 for non-small cell lung cancer, with comprehensive data expected in the second half of 2026. The company's PARP1 inhibitors EIK1003 and EIK1004 are in Phase 1/2 trials, whilst EIK1005, a WRN helicase inhibitor, has begun patient trials. As of 31 December 2025, Eikon held $336 million in cash and marketable securities. The company expects its cash, including IPO proceeds, will fund operations into the second half of 2027. Net loss for 2025 was $333.6 million, compared to $243.8 million in 2024.

Reuters
Feb 5th, 2026
Perlmutter-backed Eikon Therapeutics raises $381.2 million in IPO

Drug developer Eikon ‍Therapeutics said on Wednesday it had raised $381.2 million in its U.S. initial public offering, selling about 21.2 million shares priced at $18 apiece.

Stock Titan
Feb 5th, 2026
Eikon Therapeutics prices upsized IPO of 21.2M shares at $18, raising $381M

Eikon Therapeutics, a late-stage clinical biopharmaceutical company, has priced its upsized initial public offering of 21,177,600 shares at $18.00 per share, expecting gross proceeds of approximately $381 million before fees. The underwriters have a 30-day option to purchase an additional 3,176,640 shares. The company's shares are expected to begin trading on the Nasdaq Global Select Market on 5 February 2026 under the ticker symbol "EIKN". The offering is scheduled to close on or about 6 February 2026, subject to customary closing conditions. J.P. Morgan, Morgan Stanley, BofA Securities, Cantor and Mizuho are serving as joint book-running managers for the offering. Eikon focuses on developing innovative medicines for oncology and other areas of high unmet medical need.

Contract Pharma
Jan 27th, 2026
Integrated Biosciences Names Daniel J. Anderson CSO

Integrated Biosciences names Daniel J. Anderson CSO. Anderson will oversee the company's scientific strategy and pipeline development. Integrated Biosciences has a new Chief Scientific Officer (CSO), naming Daniel J. Anderson, PhD, to the post. Anderson joins from Eikon Therapeutics, and previously worked for Recursion Pharmaceuticals, Cleave Biosciences, and Genentech. Based in Redwood City, Calif., Integrated Biosciences is a biotechnology company combining the fields of synthetic biology, chemistry, and AI. By doing this, the company discovers small-molecule therapeutics for age-related diseases. Details of new cso's role. Anderson's role is to oversee Integrated Biosciences' scientific strategy and pipeline development. In this way, the company says Anderson's leadership will help build upon its proprietary platform. Integrated Biosciences said Anderson has advanced 10 programs into the clinic in his career. In his previous work, he has focused on cutting-edge technology and data science approaches to drug discovery. "Integrated Biosciences has built a platform that tightly couples precise biological perturbation with high-content measurements and AI-driven learning," Anderson said. "The exceptional platform has produced a pipeline with real promise for age-related diseases. I'm excited to help accelerate translation from discovery to the clinic and facilitate bringing important new medicines to patients." Integrated Biosciences leaders respond. Felix Wong, PhD, Integrated Biosciences co-founder and CEO, applauded the move. "[Anderson's] decision to join Integrated Biosciences underscores the strength of our science, platform, and the opportunity ahead," Wong said. "His track record of building high-growth teams at Eikon Therapeutics and his scientific rigor position him perfectly to help lead." Another co-founder, Max Wilson, PhD, will move into the role of Chief Technology Officer. This post will focus on advancing Integrated Biosciences' core technology platform, including next-generation AI-enabled discovery. "[Anderson] brings over 20 years of experience in biotechnology and drug discovery," Wilson said. "I'm excited to focus on scaling our technology platform alongside him."

Endpoints News
Jan 9th, 2026
Eikon files for an IPO in major test for whether biotech's rally will take the next step

Eikon files for an IPO in major test for whether biotech's rally will take the next step. Senior biopharma correspondent. Eikon Therapeutics has filed for an IPO, in what would be a bellwether for whether the optimism that has rallied the... Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

INACTIVE